Patents by Inventor Marie-José MOUTIN

Marie-José MOUTIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases
    Patent number: 11613753
    Abstract: Using chemical proteomics with a potent unique irreversible inhibitor, inventors found that major brain tubulin carboxypeptidase (TCP) is a complex of vasohibin-1 (VASH1) with the Small Vasohibin-Binding Protein (SVBP). VASH1 and its homologue vasohibin-2 (VASH2), when complexed with SVBP, exhibit robust and specific Tyr/Phe carboxypeptidase activity on microtubules. Accordingly inventors are the first to identify the enzymatic activity of vasohibin and vasohibin/SVBP complex. Knock down of vasohibins or SVBP in cultured neurons results in a marked reduction of tyrosinated ?-tubulin levels and onset of severe differentiation defects. Furthermore, knock down of vasohibins disrupts neuronal migration in developing mouse neocortex. These results establish vasohibin/SVBP complexes as TCP enzymes.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: March 28, 2023
    Assignees: LES LABORATOIRES SERVIER, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Annie Andrieux, Marie-José Moutin, Christophe Bosc, Chrystelle Aillaud, Leticia Peris, Philippe Delagrange
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING TUBULIN CARBOXYPEPTIDASES ASSOCIATED DISEASES
    Publication number: 20200407726
    Abstract: Using chemical proteomics with a potent unique irreversible inhibitor, inventors found that major brain tubulin carboxypeptidase (TCP) is a complex of vasohibin-1 (VASH1) with the Small Vasohibin-Binding Protein (SVBP). VASH1 and its homologue vasohibin-2 (VASH2), when complexed with SVBP, exhibit robust and specific Tyr/Phe carboxypeptidase activity on microtubules. Accordingly inventors are the first to identify the enzymatic activity of vasohibin and vasohibin/SVBP complex. Knock down of vasohibins or SVBP in cultured neurons results in a marked reduction of tyrosinated ?-tubulin levels and onset of severe differentiation defects. Furthermore, knock down of vasohibins disrupts neuronal migration in developing mouse neocortex. These results establish vasohibin/SVBP complexes as TCP enzymes.
    Type: Application
    Filed: October 26, 2018
    Publication date: December 31, 2020
    Inventors: Annie ANDRIEUX, Marie-José MOUTIN, Christophe BOSC, Chrystelle AILLAUD, Leticia PERIS, Philippe DELAGRANGE